A. Cns, Epidémiologie de l'infection à VIH en France, 2017.

, Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts sous la direction du Pr Philippe Morlat et sous l'égide du CNS et de l'ANRS, 2017.

D. Sur, Découvertes de séropositivité VIH et de sida. Point épidémiologique du 23 mars 2017. / Actualités / Infection à VIH et sida / VIH-sida / IST / Maladies infectieuses / Dossiers thématiques / Accueil [Internet], 2018.

, IST/Infection-a-VIH-et-sida/Actualites/Decouvertes-de-seropositivite-VIH-et-de-sida

. Oms-|-vih/sida, En finir avec le sida -Progresser vers les cibles 90-90-90 -Synthèse, 2017.

D. Sur,

H. Samji, A. Cescon, R. S. Hogg, S. P. Modur, K. N. Althoff et al.,

, Life expectancy of individuals on combination antiretroviral therapy in highincome countries: a collaborative analysis of 14 cohort studies. The Lancet, PloS One, vol.8, issue.12, pp.293-302, 2008.

U. F. , Santé Faculté des Sciences Pharmaceutiques 7. HIV and Aging

D. Sur,

, HIV Among People Aged 50 and Over | Age | HIV by Group | HIV/AIDS | CDC, 2017.

M. J. Disponible-sur-;-prince, F. Wu, Y. Guo, G. Robledo, L. M. et al., The burden of disease in older people and implications for health policy and practice, Lancet Lond Engl. 7 févr, vol.385, issue.9967, pp.549-62, 2015.

K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke et al.,

D. A. Piggott, K. M. Erlandson, and K. E. Yarasheski, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs, vol.380, pp.340-348, 2012.

G. Guaraldi, G. Orlando, S. Zona, M. Menozzi, F. Carli et al.,

, Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population, Clin Infect Dis. 1 déc, vol.53, issue.11, pp.1120-1126, 2011.

U. F. Santé, Faculté des Sciences Pharmaceutiques 15. Sabin CA, Reiss P. Epidemiology of ageing with HIV: what can we learn from cohorts?, AIDS. juin, vol.31, p.121, 2017.

J. Schouten, F. W. Wit, I. G. Stolte, N. A. Kootstra, M. Van-der-valk et al., Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 déc, vol.59, issue.12, pp.1787-97, 2014.

, Workshop on HIV Infection and Aging: What Is Known and Future Research Directions

S. Nozza, A. Malagoli, L. Maia, A. Calcagno, E. Focà et al., Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août, vol.47, issue.4, pp.542-53, 2008.

, Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study, J Antimicrob Chemother, vol.72, issue.10, pp.2879-86, 2017.

E. Molas, S. Luque, A. Retamero, D. Echeverría-esnal, A. Guelar et al., Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team, HIV Clin Trials, 2017.

, Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population

, Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp. 1 sept, vol.41, issue.5, pp.618-642, 2017.

H. Liverpool and . Interactions, Sida et VIH [Internet, 2018.

, Santé Faculté des Sciences Pharmaceutiques 23. VIH et transmission mère-enfant, Presse Médicale. 1 juin, vol.43, issue.6, pp.691-698, 2014.

, VIH Phase 1 -Primo-infection

, Actuel.html, vol.25

A. Lifson, G. Grandits, E. Gardner, M. Wolff, P. Pulik et al., Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial: Quality of life assessment in START, HIV Med. avr, vol.16, pp.88-96, 2015.

J. Bressy, Prise en charge du VIH -Recommandations du groupe d'experts

, Conseil national du sida et des hépatites virales, 2017.

D. Sur,

D. Sur,

P. Dorosz, D. Durand, L. Jeunne, and C. , Guide pratique des médicaments. Paris: Maloine; 2014. 29. VIDAL -Vincristine (substances) [Internet], 2018.

V. Disponible-sur-;-jurus, S. Bossaert, and B. Charpiat, Estimation du nombre et de la nature des interactions médicamenteuses concernant les médicaments antirétroviraux, J Pharm Clin. 1 juill, vol.25, issue.3, pp.153-162, 2006.

U. F. Santé, Faculté des Sciences Pharmaceutiques 31. WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

C. Disponible-sur-;-gilks and M. Vitoria, Traitement antirétroviral de l'infection à VIH chez l'adulte et l'adolescent en situation de ressources limitées : vers un accès universel : recommandations pour une approche de santé publique, 2008.

D. Sur,

J. Bezin, M. Duong, R. Lassalle, C. Droz, A. Pariente et al., The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf. 1 août, vol.26, issue.8, pp.954-62, 2017.

E. M. Gardner, M. P. Mclees, J. F. Steiner, D. Rio, C. Burman et al., The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars, vol.52, issue.6, pp.793-800, 2011.

K. J. Siefried, L. Mao, L. A. Cysique, J. Rule, M. L. Giles et al.,

, Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy, AIDS. janv, vol.32, issue.1, pp.35-48, 2018.

H. Spall, A. Toren, A. Kiss, and R. A. Fowler, Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling Review, JAMA. 21 mars, vol.297, issue.11, pp.1233-1273, 2007.

L. Cuzin, C. Katlama, L. Cotte, P. Pugliese, A. Cheret et al.,

U. F. , Santé Faculté des Sciences Pharmaceutiques Ageing with HIV: do comorbidities and polymedication drive treatment optimization?, HIV Med, vol.18, issue.6, pp.395-401

J. A. Cooper, C. A. Cadogan, S. M. Patterson, N. Kerse, and M. C. Bradley,

, Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review, BMJ. 1 déc, vol.5, issue.12, 2015.

M. Hentzien, M. Dramé, C. Allavena, C. Jacomet, M. Valantin et al.,

, Impact of age-related comorbidities on five-year overall mortality among elderly HIVinfected patients in the late HAART era -Role of chronic renal disease, American Geriatrics Society, vol.20, issue.4, pp.2227-2273, 2015.

C. T. Naugler, C. Brymer, P. Stolee, and Z. A. Arcese, Development and validation of an improving prescribing in the elderly tool, Can J Clin Pharmacol J Can Pharmacol Clin, vol.7, issue.2, pp.103-110, 2000.

D. O'mahony, O. 'sullivan, D. Byrne, S. O'connor, M. N. Ryan et al.,

, STOPP/START criteria for potentially inappropriate prescribing in older people: version

, Age Ageing. mars, vol.44, issue.2, pp.213-221, 2015.

D. O'mahony, P. Gallagher, C. Ryan, S. Byrne, H. Hamilton et al.,

, STOPP & START criteria: A new approach to detecting potentially inappropriate prescribing in old age, Eur Geriatr Med. févr, vol.1, issue.1, pp.45-51, 2010.

U. F. Baecke, C. Gyssens, I. C. Decoutere, L. Van-der-hilst, J. Messiaen et al., Santé Faculté des Sciences Pharmaceutiques 44

, Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study, Neth J Med. juill, vol.75, issue.6, pp.235-275, 2017.

B. Jakeman, M. Nasiri, L. Ruth, C. Morse, S. Mahatme et al., Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients, Iniesta-Navalón C, Franco-Miguel JJ, Gascón-Cánovas JJ, vol.51, pp.365-72, 2017.

L. Redondo, Identification of potential clinically significant drug interactions in HIVinfected patients: a comprehensive therapeutic approach, HIV Med. mai, vol.16, issue.5, pp.273-282, 2015.

C. Holtzman, C. Armon, E. Tedaldi, J. S. Chmiel, K. Buchacz et al.,

, Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population, J Gen Intern Med, vol.28, issue.10, pp.1302-1312, 2013.

A. Tseng, L. Szadkowski, S. Walmsley, I. Salit, and J. Raboud, Association of Age With Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV-Positive Patients, Ann Pharmacother, vol.47, issue.11, pp.1429-1468, 2013.

D. A. Rastegar, A. M. Knight, J. S. Monolakis, J. G. Evans-jones, L. E. Cottle et al., Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mai, vol.43, issue.7, pp.1419-1440, 2006.

U. F. Miller, C. D. El-kholi, R. Faragon, J. J. Lodise, and T. P. , Prevalence and Risk Factors for Clinically Significant Drug Interactions with Antiretroviral Therapy, Santé Faculté des Sciences Pharmaceutiques 51, vol.27, pp.1379-86, 2007.

H. Liverpool, +. Interactions--ritonavir, and . Fluticasone, , 2018.

H. Liverpool, +. Interactions--atazanavir, and . Lansoprazole, , 2018.

D. Sur,

U. Mhra-gov, . Spc, and . Lansoprazole, , 2018.

J. Thorel, C. Mccambridge, A. Piau, M. Secher, and É. Magre,

, Proton pump inhibitors: Real indication or trivialized prescription?, Therapie. déc, vol.71, issue.6, pp.589-93, 2016.

M. Dipanda, L. Pioro, M. Buttard, P. Athis, S. Asgassou et al.,

, Evaluation of the prescription of proton pump inhibitors in persons aged 75years and older in a geriatric acute-care unit, Am J Gastroenterol. août, vol.72, issue.6, p.1085, 2016.

U. F. Althoff, K. N. Smit, M. Reiss, P. Justice, and A. C. , HIV and Ageing: Improving Quantity and Quality of Life, Curr Opin HIV AIDS. sept, vol.11, issue.5, pp.527-563, 2016.

D. Sur,

, Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of

H. F. Günthard, M. S. Saag, C. A. Benson, C. Del-rio, J. J. Eron et al.,

, Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel, JAMA. 12 juill, vol.316, issue.2, pp.191-210, 2016.

R. Y. Chen, N. A. Accortt, A. O. Westfall, M. J. Mugavero, J. L. Raper et al.,

, Distribution of Health Care Expenditures for HIV-Infected Patients, Clin Infect Dis. 1 avr, vol.42, issue.7, pp.1003-1013, 2006.

, EU marketing authorisation for Juluca (dolutegravir/rilpivirine)

D. Sur,

, Phase III studies for dolutegravir and lamivudine, p.31, 2018.

D. Sur, U.F.R. Santé Faculté des Sciences Pharmaceutiques, vol.66

, Annexe A : utilisation des données du SNIIRAM

, SNIIRAM comportait plus d'une centaine de tables. Un aperçu des fichiers reçus est illustré ci-dessous : U.F.R. Santé Faculté des Sciences Pharmaceutiques